A Phase III, Prospective, Double-Masked, Randomized, Multi-Center, Active-Controlled, Parallel Group Comparison Study Assessing the Ocular Hypotensive Efficacy of Reformulated PG324 Ophthalmic Solution in Subjects With Elevated Intraocular Pressure
Status: Recruiting
Location: See all (30) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosis of open-angle glaucoma or ocular hypertension in both eyes;
• Unmedicated intraocular pressure measurements in the study eye as specified in the protocol;
• Corrected distance visual acuity equal to or better than 20/100 in the study eye.
Locations
United States
Alabama
Trinity Research Group
NOT_YET_RECRUITING
Dothan
Arizona
Eye Doctors of Arizona
RECRUITING
Phoenix
California
Orange County Ophthalmology Medical Group
RECRUITING
Garden Grove
United Medical Research Institute
RECRUITING
Inglewood
Eye Research Foundation
RECRUITING
Newport Beach
North Bay Eye Associates
NOT_YET_RECRUITING
Petaluma
Sacramento Eye Consultants
NOT_YET_RECRUITING
Sacramento
Florida
Central Florida Eye Specialists
NOT_YET_RECRUITING
Deland
Glaucoma Specialists of South Florida
NOT_YET_RECRUITING
Delray Beach
East Coast Institute for Research, LLC
NOT_YET_RECRUITING
Jacksonville
Central Florida Eye Associates
RECRUITING
Lakeland
Lee Shettle Eye
NOT_YET_RECRUITING
Largo
The Eye Institute of West Florida
NOT_YET_RECRUITING
Largo
Georgia
North Georgia Eye Associates
NOT_YET_RECRUITING
Gainesville
Coastal Research Associates
NOT_YET_RECRUITING
Roswell
Kansas
Kannarr Eye Care LLC
NOT_YET_RECRUITING
Pittsburg
Massachusetts
NorthEast Eye Research Associates, LLC
NOT_YET_RECRUITING
Westborough
Mississippi
Coldwater Vision Research
NOT_YET_RECRUITING
Coldwater
North Carolina
Albemarle Eye Center
NOT_YET_RECRUITING
Elizabeth City
Oculus Research, Inc.
NOT_YET_RECRUITING
Garner
CORE, Inc.
NOT_YET_RECRUITING
Shelby
Nevada
Las Vegas Eye Institute
NOT_YET_RECRUITING
Henderson
New York
Rochester Ophthalmological Group
NOT_YET_RECRUITING
Rochester
Ohio
Midwest Eye Center
NOT_YET_RECRUITING
Cincinnati
University Hospitals Cleveland Medical Center
NOT_YET_RECRUITING
Cleveland
Pennsylvania
Scott & Christie and Associates, PC
NOT_YET_RECRUITING
Cranberry Township
Tennessee
Southern College of Optometry
NOT_YET_RECRUITING
Memphis
Total Eye Care, PA
NOT_YET_RECRUITING
Memphis
Utah
The Eye Institute of Utah
NOT_YET_RECRUITING
Salt Lake City
Virginia
Piedmont Eye Center
NOT_YET_RECRUITING
Lynchburg
Contact Information
Primary
Alcon Call Center
alcon.medinfo@alcon.com
1-888-451-3937
Time Frame
Start Date: 2025-09-02
Estimated Completion Date: 2026-05
Participants
Target number of participants: 470
Treatments
Experimental: Reformulated PG324
One drop of netarsudil 0.01%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months
Active_comparator: PG324
One drop of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months
Related Therapeutic Areas
Sponsors
Leads: Alcon Research